Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes
- 26 June 2007
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 9 (5), 724-732
- https://doi.org/10.1111/j.1463-1326.2007.00743.x
Abstract
To evaluate the efficacy and safety of adding biphasic insulin aspart 30 (BIAsp30; NovoMix 30) to existing oral antidiabetic agents (OADs) vs. optimizing OADs in a subgroup of Western Pacific patients with type 2 diabetes inadequately controlled on oral monotherapy or oral combination therapy.This 26-week, multi-centre, open-labelled, randomized, two-arm parallel trial consisted of a 2-week screening period, followed by 24 weeks of treatment. Subjects randomized to BIAsp30 treatment (n = 129) received BIAsp30 once daily (o.d.) at dinnertime between Week 2 and Week 14, and those not reaching treatment targets were switched to twice daily (b.i.d.) BIAsp30 at Week 14 (n = 50). Subjects randomized to the OAD-only arm (n = 63) continued with their previous OAD treatment and, in an attempt to reach treatment goals, the dose was optimized (but OAD unchanged) in accordance to local treatment practice and labelling.Significantly greater reductions in HbA(1c) over Weeks 0-13 with BIAsp30 (o.d.) vs. OAD-only treatment (1.16 vs. 0.58%; p < 0.001), and over Weeks 0-26, with BIAsp30 (o.d.) and BIAsp30 (b.i.d.) treatments vs. OAD-only treatment (1.24 vs. 1.34 vs. 0.67%; p < 0.01). Hypoglycaemic episodes were reported in 54% of the patients in BIAsp30 (o.d. and b.i.d. pooled) and 30% of the patients in OAD-only group. All episodes were minor or symptomatic, except for one in each treatment group, which was major.Initiating BIAsp30 treatment is a safe and more effective way to improve glycaemic control in Western Pacific patients with type 2 diabetes inadequately controlled with oral monotherapy or oral combination therapy compared with optimizing oral combination therapy alone. In patients not reaching treatment target on BIAsp30 (o.d.), treatment with BIAsp30 (b.i.d.) should be considered.Keywords
This publication has 15 references indexed in Scilit:
- Type 2 diabetes in youth from the Western Pacific region: glycaemic control, diabetes care and complicationsCurrent Medical Research and Opinion, 2006
- Attainment of glycaemic goals in type 2 diabetes with once‐, twice‐, or thrice‐daily dosing with biphasic insulin aspart 70/30 (The 1‐2‐3 study)Diabetes, Obesity and Metabolism, 2005
- Determinants of Response to Insulin Therapy Following Failure of Oral Agents in Type 2 DiabetesDiabetes Care, 2005
- What's So Tough About Taking Insulin? Addressing the Problem of Psychological Insulin Resistance in Type 2 DiabetesClinical Diabetes, 2004
- Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 DiabetesDiabetes Care, 2004
- Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapyClinical Therapeutics, 2003
- Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugsThe Lancet, 1998
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Glycemic Control in a Sample of Black and White Clinic Patients with NIDDMDiabetes Care, 1994
- UK Prospective Diabetes Study XII: Differences Between Asian, Afro‐Caribbean and White Caucasian Type 2 Diabetic Patients at Diagnosis of DiabetesDiabetic Medicine, 1994